stockrow
Friday 6 November 2026
Export TARS’s income statement to Excel — free account
Tarsus Pharmaceuticals, Inc.
TARS Healthcare Biotechnology
Tarsus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $451.4 million, up 146.7% from fiscal 2024.
- Revenue
- +63.9%
- EPS
- −4,699.1%
- Free cash flow
- −144.1%
- Total debt
- +0.90%
Quarter to September 2026, against a year earlier
68.81
1.29
+1.91%
Follow TARS
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 5 | 5 | 5 |
+8 more TTM periods Free account |
| (319.84%) | (13.68%) | (13.96%) | (23.39%) | ||
| (135.04%) | (8.40%) | (8.92%) | (14.14%) | ||
ROIC |
0.00% | 0.00% | (96.77%) | 0.00% | |
Return on Tangible Assets |
(293.79%) | (11.43%) | (11.73%) | (16.66%) | |
Average Days of Receivables |
54.63 | 59.18 | 79.95 | 70.44 | |
Free Cash Flow per Share |
0.70 | 1.29 | (0.73) | (0.53) | |
Free Cash Flow |
32.44 | 56.00 | (31.54) | (22.31) | |
Capital Expenditures |
(17.46) | (18.15) | (15.09) | (9.86) | |
| Other line items | |||||
Cash ROIC |
6.67% | 6.44% | (3.89%) | (2.68%) | |
Accounts Receivable Turnover |
7.73 | 7.65 | 5.90 | 6.68 | |
Accounts Payable Turnover |
0.67 | 0.69 | 0.69 | 2.38 | |
Inventory Turnover |
10.30 | 9.88 | 9.58 | 8.78 | |
Average Days of Payables |
273.33 | 359.59 | 252.60 | 194.93 | |
Days of Inventory on Hand |
40.64 | 39.21 | 47.86 | 52.01 | |
Tax Rate |
0.01 | 0.13 | 0.05 | 0.00 | |
Research and Development Expense of Revenue |
16.94% | 14.46% | 13.51% | 14.25% | |
Selling, General and Administrative Expense of Revenue |
85.87% | 86.82% | 89.47% | 94.67% | |
Share Based Compensation of Revenue |
9.79% | 8.55% | 8.74% | 9.24% | |
Interest Coverage |
(80.17) | (5.54) | (5.74) | (7.94) | |
Operating CF/Net income |
(0.07) | (1.60) | 0.34 | 0.19 | |
Depreciation/Fixed assets |
0.03 | (0.05) | (0.15) | (0.26) | |
Capex/Depreciation |
(30.10) | 16.55 | 5.78 | 3.21 | |
Revenue per Share |
14.70 | 13.97 | 12.46 | 10.80 | |
Operating CF per Share |
1.07 | 1.71 | (0.38) | (0.30) | |
Capex per Share |
(0.38) | (0.42) | (0.35) | (0.24) | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.02 |
Columns are period end dates · fundamentals updated 5 Nov 2026